Drug intelligence / Profile preview

AKS-197d

Development stage: Preclinical
Lead developer: Akston Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

AKS-197d is a monoclonal antibody therapeutic candidate developed by Akston Biosciences for the treatment of canine oncology. Engineered using the company's proprietary Ambifect platform, the drug is designed to target and down-regulate the insulin-like growth factor (IGF) receptor. By binding to this receptor, AKS-197d inhibits IGF signaling pathways that are frequently exploited by tumor cells for growth, survival, and metastasis. As a species-specific biologic, it is specifically optimized for use in dogs, aiming to provide a targeted antineoplastic therapy with reduced off-target effects in veterinary patients.

Targets

IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on AKS-197d.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AKS-197d.

Explore the full profile